Akari Therapeutics PLC (AKTX)
1.30
+0.06
(+4.84%)
USD |
NASDAQ |
Nov 22, 16:00
1.30
0.00 (0.00%)
After-Hours: 20:00
Akari Therapeutics Cash from Financing (Quarterly): -0.443M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -0.443M |
| June 30, 2024 | 7.763M |
| March 31, 2024 | 1.514M |
| December 31, 2023 | 3.517M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.291M |
| March 31, 2023 | 3.212M |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 12.37M |
| December 31, 2021 | 1.116M |
| September 30, 2021 | 11.18M |
| June 30, 2021 | 1.994M |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 5.992M |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 9.204M |
| March 31, 2020 | 9.878M |
| December 31, 2019 | 2.776M |
| September 30, 2019 | 8.398M |
| June 30, 2019 | 1.316M |
| March 31, 2019 | 0.1577M |
| Date | Value |
|---|---|
| December 31, 2018 | 0.1534M |
| September 30, 2018 | 0.3466M |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 15.67M |
| September 30, 2017 | 0.00 |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | -3.060M |
| September 30, 2015 | 72.61M |
| June 30, 2015 | -0.5087M |
| March 31, 2015 | |
| December 31, 2014 | 3.893M |
| September 30, 2014 | -7.877M |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 8.219M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.443M
Minimum
Sep 2024
12.37M
Maximum
Mar 2022
3.909M
Average
2.385M
Median
Cash from Financing (Quarterly) Benchmarks
| DBV Technologies SA | 0.007M |
| Ascendis Pharma AS | -- |
| Cellectis SA | -4.218M |
| Adaptimmune Therapeutics PLC | 25.00M |
| Biodexa Pharmaceuticals PLC | -- |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -1.49M |
| Free Cash Flow | -14.84M |
| Free Cash Flow Per Share (Quarterly) | -0.1222 |
| Free Cash Flow Yield | -139.5% |